USPTO serial 98288528
PATIENTS FIRST. POWERED BY EVIDENCE.
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- ORDOGNE, ROBERT J
- Law office
- TMO LAW OFFICE 126
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PATIENTS FIRST. POWERED BY EVIDENCE.?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Blue Bell, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa Casey Spaniel
Lisa Casey Spaniel BLANK ROME LLPONE LOGAN SQUARE8TH FLOORPHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | downloadable computer software, computer software platforms, and mobile applications featuring digital assets and artificial intelligence for database management, analytics, modeling, monitoring, storage, validation, compliance, reimbursement management, scheduling, progress monitoring, benefits verification, reimbursements and case management in the field of Clinical Research, Safety Services, Risk Evaluation and Mitigation, Patient Support Services, Evidence Development and Data Analysis | ACTIVE | — |
| 016 | printed materials, namely, brochures, manuals and handbooks featuring topics relating to health, medical and pharmaceutical education, training and testing in connection with patient assistance programs for the pharmaceutical and healthcare industries | ACTIVE | — |
| 035 | consulting services in the cost management of health care, namely, cost management for the health care benefit plans of others, including health care benefit plans that have co-pay cards; medical cost management and administering medication reimbursement programs for others to improve health, affordability and patient experience; business consulting services featuring business analytics and information in the healthcare and pharmaceutical industries during drug development and commercialization, namely, business analytics and information in the fields of real world evidence, health economics, outcomes research, payer research and market access studies; strategic business data analysis and business advice regarding benefit cost management, pharmaceutical end-user behavior and healthcare use behavior; business consulting services in the fields of business risk minimization, business risk mitigation and business Risk Evaluation and Mitigation Strategies; business management of in-home care coordination services, business organization and management of a nationwide home health network, business organization and management of a nationwide injection network; business administration services, namely, customer relationship management services design and implementation of customer services solutions via various technology partnerships and custom configurations connecting vendors and services and hybrid operating platform designs and deployments; Business administration of co-pay programs for reimbursement of co-pays and access to medication discounts, benefit verification, claims administration and other support for reimbursement and access to benefits | ACTIVE | — |
| 036 | Consulting services in the payment management of health care, namely, co-pay cards, therapeutic access, reimbursement, analysis of manufacturer program designs and medication discount benefits | ACTIVE | — |
| 038 | webcasting services featuring topics in the field of health, medical care and pharmaceutical industries | ACTIVE | — |
| 041 | educational, training and educational testing services, namely, conducting seminars, conferences and presentations featuring topics in the field of health, medical care and pharmaceutical industries; training and educational services, namely, conducting programs in the fields of health, medical care and pharmaceutical industries; training and educational services, namely, providing non-downloadable webcasts in the fields of health, medical care and pharmaceutical industries | ACTIVE | — |
| 042 | medical and scientific research, namely, conducting clinical trials for others; basic and clinical research in the field of heath care and medicine; providing on-line non-downloadable software, computer software platforms, and applications featuring artificial intelligence and digital assets used to administer, advise, monitor, analyze or generate information related to Clinical Research, Safety Services, Risk Evaluation and Mitigation, Patient Support Services, Evidence Development and Data Analysis; non-downloadable software as a service (SAAS) technology platforms for database management, analytics, modeling, monitoring, storage, validation, compliance, payment management, scheduling, progress monitoring, benefits verification, reimbursements and cost management related to Clinical Research, Safety Services, Risk Evaluation and Mitigation, Patient Support Services, Evidence Development and Data Analysis; providing on-line non-downloadable software, platforms, and mobile applications featuring digital assets and artificial intelligence for database management, analytics, modeling, monitoring, storage, validation, compliance, payment management, scheduling, progress monitoring, benefits verification, reimbursements and cost management in the field of clinical research, safety services, risk evaluation and mitigation, patient support services, evidence development and data analysis; scientific research consulting services in the field of pharmacovigilance strategies to ensure regulatory compliance and patient safety in clinical trials and marketed pharmaceuticals involving human subjects; scientific research consulting services in the field of epidemiology; pharmaceutical product safety testing and consultancy efficacy services for the purposes of, namely, risk mitigation and pharmacovigilance services, prescription drug monitoring programs, analyzing clinical data in healthcare databases, clinical trials, health economics and outcomes research in the fields of healthcare and pharmaceuticals, organizing, managing, and tracking data during development of a clinical trial, creating and updating clinical guidelines in the fields of healthcare and pharmaceuticals | ACTIVE | — |
| 044 | healthcare services in the nature of remote and in-person patient support services, namely, nursing services, dose administration in the nature of patient engagement to ensure adherence to dosing protocols, and patient medical diagnostic monitoring services | ACTIVE | — |
| 045 | consultation services in the field of research compliance, namely, regulatory compliance consultation services in the field of clinical trials involving human subjects; regulatory compliance consultation services in the field of informed consent protocols for clinical trial participants, Pregnancy registries, Pregnancy Root cause analysis, Risk Evaluation and Mitigation Strategy administration, Observational Research Real world Evidence, Real world Data, Knowledge Attitude and Behavior Surveys, Proprietary Risk Evaluation and Mitigation Strategy Platform, Expanded Patient Access Programs, Clinical Trial and Post Marketing Case Processing, Post Marketing Commitments, Post Marketing Requirements, Risk Minimization Plans, Risk Evaluation and Mitigation, Patient HUB, Benefit Investigation, Interventional Clinical Trials, Natural History Studies, Pragmatic Studies Design and Administration of Outcomes Based Agreements and value based agreements, Federated Registries, Integrated Registries, Decentralized Studies, and Patient Recruitment Strategies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by United BioSource LLC
- Other trademarks in Class 009
- Other trademarks in Class 016
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 038
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named PATIENTS FIRST. POWERED BY EVIDENCE.
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 9, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 9, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 9, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 9, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 7, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 7, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Apr 7, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 7, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 7, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 30, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 30, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 29, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2024 | LOPE | LETTER OF PROTEST EVIDENCE REVIEWED - ACTION TAKEN | — |
| Jun 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 18, 2024 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Jan 22, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 1, 2023 | NWAP | NEW APPLICATION ENTERED | — |